"4+7" Cardiovascular Drug Terminal Market Changes

A few days ago, the fifth batch of national centralized procurement of drugs is about to be gradually implemented.

In the first batch of "4+7" lists, there are 30 in total in terms of generic names of drugs

The overall price of designated varieties has dropped significantly

Based on the PDB domestic sample hospital market data, the overall price trends of the above 10 generic names from 2017 to the first half of 2021 are as follows.

Figure 1 The overall price trend of cardiovascular system drugs purchased in sample hospital market (2017-2021H1, yuan)

Specified analysis of designated varieties (5 varieties in total)

Taking into account the number of dosage forms and specifications corresponding to different varieties in the "4+7" list, the product specification analysis for the more diverse dosage forms and specifications, a total of 5 varieties, including atorvastatin, rosuvastatin, and losartan , Irbesartan, lisinopril

Based on PDB's domestic sample hospital market data, the market share and price changes of the four product specifications of atorvastatin from 2017 to the first half of 2021 are calculated separately.

Figure 2 Market share and price trend of atorvastatin designated product in the sample hospital market (2017-2021H1)

Based on the PDB domestic sample hospital market data, the market share and price changes of the four product specifications of rosuvastatin from 2017 to the first half of 2021 are calculated separately.

Figure 3 Market share and price trend of rosuvastatin designated product in the sample hospital market (2017-2021H1)

Based on PDB's domestic sample hospital market data, the market share and price changes of the four product regulations of Losartan from 2017 to the first half of 2021 are calculated separately.

Figure 4 The market share and price trend of losartan designated product regulations in the sample hospital market (2017-2021H1)

Based on the PDB domestic sample hospital market data, the market share and price changes of the four product specifications of Irbesartan from 2017 to the first half of 2021 are calculated separately.

Figure 5 The market share and price trend of irbesartan designated products in the sample hospital market (2017-2021H1)

Based on PDB's domestic sample hospital market data, we separately count the market share and price changes of lisinopril's four product specifications from 2017 to the first half of 2021.

Figure 6 Market share and price trend of lisinopril designated product regulations in the sample hospital market (2017-2021H1)

Enterprise analysis of designated species (4 species in total)

Taking into account the number of dosage forms and specifications corresponding to different varieties in the "4+7" list, the company analysis of the dosage forms and specifications is more concentrated, and there are a total of 4 varieties, including fosinopril, enalapril, and captopril.

Based on PDB’s domestic sample hospital market data, we separately counted the market share and price changes of the two companies of Fosinopril (10mg tablets) from 2017 to the first half of 2021.

Figure 7 The market share and price trend of Fosinopril in the sample hospital market (2017-2021H1)

Based on PDB's domestic sample hospital market data, statistics on the market share and price changes of enalapril (5mg tablets, 10mg tablets, 5mg capsules) of TOP3 companies from 2017 to the first half of 2021 can be found, Yangtze River Group occupies an absolute dominant position, from 84% in 2017-2018 to 90% in 2019, and finally stabilized at 95% in 2020-2021

Figure 8 The market share and price trend of enalapril TOP3 companies in the sample hospital market (2017-2021H1)

Based on PDB's domestic sample hospital market data, we separately counted the market share and price changes of TOP5 companies with captopril (25mg tablets) from 2017 to the first half of 2021.

Figure 9 Market share and price trend of TOP5 Captopril companies in the sample hospital market (2017-2021H1)

Based on the market data of domestic sample hospitals from PDB, the market share and price changes of TOP3 companies with compound irbesartan hydrochlorothiazide (162.

Figure 10 The market share and price trend of TOP3 compound irbesartan hydrochlorothiazide companies in the sample hospital market (2017-2021H1)